PUTRAJAYA (Jan 27): Malaysia’s first Covid-19 vaccine clinical trial began today in nine hospitals, involving some 3,000 volunteers, Health Minister Datuk Seri Dr Adham Baba said.
The Phase 3 clinical trial of the vaccine developed and sponsored by China's Institute of Medical Biology Chinese Academy of Medical Sciences (IMBCAMS)
Cansino still not settle nego with Msia kah. why so slow lah. Mana tau later another brand 3rd phase trial approved still havent sign with cansino kah. Hope cansino order not so slow lah. Correct?
Dont worry... it is just a matter of time Not now, but slightly later.. You think Solu crazy enough to setup a plant without having any plan and pre-discussion... This is not makcik goreng pisang stall... this is serius business...
waiting waiting waiting. Nov wait until Dec. yilek. Dec wait until Jan yilek lagi kah. Now Jan ending say wait Feb. No other choice other than wait lah. Correct?
Chicken egg only need average 21 days to hatch. Here 2 mths already still havent hatch. Look like the eggs not ordinary chicken eggs lah. Must be dinosaur eggs lah. fossil eggs kah. Correct?
cansino still far behind sinovac n sinopharm. no doubt about it. from the pre order qty from the world. more or less can tell cansino is trailing from behind with the least order so far. Correct?
One issue is cansino cost is higher and need to cut down the price in order to capture the market. What cansino is doing now is supply in bulk and need local company to refill it. Like this need local company with refilling plant then can sell to the country. Correct?
UlarSawa, where you get the infor that cansino cost is higher? What prove you have??? Everyone knows cansino only require 1 dose where else most other vaccine require 2 dose! Dont simply said something that you yourself is unsure off.
UlarSawa, even govt ordered other vaccine and cansino no yet, why you so concern about this counter? If ppl want to buy they will buy. No one force anyone to buy. Why put so much effort here?
Russia may give China's CanSino vaccine first global approva (Jan 15): CanSino Biologics Inc.’s Russian partner expects local authorities to register the Chinese company’s Covid-19 vaccine soon, potentially marking the first approval for use of the inoculation outside of China.
“All registration procedures have been completed, we expect to get the registration certificate in days,” Nikolay Dodonov, head of Petrovax Pharm’s medical department, said in a phone interview.
The CanSino vaccine is currently undergoing Phase 3 trials and has been granted military approval in China, which is more limited than emergency authorization.
With the recent announcement of MCO 2.0, many parents have realised that some form of hybrid learning (a combination of in person and online) could be the future of learning. Learning through Zoom, Google Classroom, See Saw and tools will increasingly be used by education institutions to deliver teaching and learning to children of different ages
Russia is among the first countries to offer universal access to Covid-19 vaccines, with President Vladimir Putin this week ordering authorities to let anyone who wants sign up for an inoculation. It currently has two domestic vaccines registered for use.
Petrovax, owned by the country’s richest man, Vladimir Potanin, got permission for a local Phase 3 trial of the CanSino vaccine in August and applied to register it in November, according to Dodonov.
Petrovax completed injections of 500 volunteers in its local trial in November and has analyzed the results of 200 so far, Dodonov said. Of those assessed, 149 received the inoculation and had antibody levels four times higher than the minimum threshold for immunity, he said.
Petrovax, which is also helping conduct CanSino’s international trial in Russia, plans to complete its study by May.
NEW YORK (Reuters) - Pfizer Inc and BioNTech’s COVID-19 vaccine appeared to lose only a small bit of effectiveness against an engineered virus with three key mutations from the new coronavirus variant found in South Africa, according to a laboratory study conducted by the U.S. drugmaker.
eading Chinese COVID-19 vaccine producers including Sinopharm and Sinovac will charge the government 200 yuan ($30.57) per dose, as East China's Jiangsu becomes the latest province to purchase two types of domestically developed inactivated vaccines for emergency use at this wholesale price, according to a public document posted on the official website on Tuesday.
The price is the same as the one several other provinces, such as East China's Zhejiang Province and Southwest China's Sichuan Province, previously paid for COVID-19 vaccines.
The latest document shows that two inactivated vaccines negotiated in a government contract are from two leading producers -- Sinopharm and Sinovac, but did not specify the number of doses from each manufacturer.
Southwest China's Sichuan Province has begun coronavirus vaccine emergency use for 12 types of high-risk groups -- about 2 million people -- with inoculation scheduled to be completed by the end of the year, media reported.
It was reported that inactivated COVID-19 vaccines were the main vaccines to be administered in Sichuan. The vaccine costs 200 yuan ($30.62) per dose, the same as the one used in Zhejiang Province launched in October.
In a recent online poll involving around 150 participants on Sina Weibo, more than 80 percent people believed the price is affordable and acceptable.
US pharmaceutical firm Pfizer recently announced its wholesale price negotiated in a government contract at $20 per dose, while Moderna will charge governments between $10 and $50 per dose, media reported.
CanSino, another Chinese frontrunner vaccine producer, has not yet disclosed its vaccine price.
Cansino boss said one lah. you go googles other news portal lah. Need to reduce price by selling in bulk to the country. Need to fight in price lah. Correct?
The fact is solution plant not ready yet right. report stated end of 2nd Qtr or 3rd qtr right. everything also not approved yet. have to wait right. Then why not counting purple notes better than counting eggs again right. Correct
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
UlarSawa
35,552 posts
Posted by UlarSawa > 2021-01-27 22:03 | Report Abuse
katak also tired sleeping in the well kah. Correct?